News

News and Press Releases
Research | Drug Pipeline | Clinical Trials Positive Late Stage Study Results for Next-Generation, Triple-Combination Modulator

Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.

| 3 min read
Research | Drug Pipeline | Clinical Trials Phase 2 Study Shows Promising Results for Potential Mucus Clearance Drug

A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.

| 2 min read
Clinical Trials | Researcher Resources | Cystic Fibrosis Foundation Therapeutics (CFFT) Drug Company Ends Ataluren Program for CF Nonsense Mutations

PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations. 

| 3 min read
About the CF Foundation | Public Policy | Clinical Trials The Cystic Fibrosis Foundation Celebrates Passage of the Ensuring Access to Clinical Trials Act of 2015

CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases

| 5 min read
About the CF Foundation | Public Policy | Clinical Trials CF Foundation–Championed Bill Passes Senate, then House

The House of Representatives has passed a vote on the Ensuring Access to Clinical Trials Act (EACT), which is now set to go to the President for his signature.

| 2 min read
About the CF Foundation | Public Policy | Clinical Trials Cystic Fibrosis Foundation Provides Expert Testimony to Congress in Support of the Ensuring Access to Clinical Trials Act

Bill Would Remove Barrier to Clinical Research for Rare Diseases by Ensuring that Clinical Trial Participants Don't Lose Critical Health Benefits

| 3 min read
About the CF Foundation | Public Policy | Clinical Trials CF Foundation Supports EACT with Testimony to Congress

Cystic Fibrosis Foundation Vice President of Therapeutics Development Dr. Michael Boyle testified today at a hearing in front of the House Energy and Commerce Committee's Subcommittee on Health. He urged members to support H.R. 209, the Ensuring Access to Clinical Trials Act (EACT), which would make permanent a law enabling people to participate in clinical trials without the fear of losing critical benefits.

| 3 min read
About the CF Foundation | Public Policy | Clinical Trials Legislation Introduced to Protect Access to Clinical Trials for People with CF

Legislation introduced today will help more people with cystic fibrosis, and other rare diseases, participate in clinical trials without fear of losing important benefits or health coverage. The bill is sponsored by a bipartisan group of senators and legislators.

| 2 min read
About the CF Foundation | Clinical Trials | Clinician Resources New CFF Program Helps Bring More Research Staff to Clinical Trials Network

The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).

| 2 min read